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There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma. Gemcitabine is a novel
nucleoside analogue, which acts synergistically with cisplatin both in vitro and in clinical studies. We evaluated the combination of
gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin’s and
non-Hodgkin’s lymphoma. The best-achieved response rate (RR) was 79% (95% CI 64–91), with a complete RR of 21%. In patients
with chemo-resistant disease, the RR was 63%. Myelosuppression was the main toxicity, the incidence of Grade 3 or 4 anaemia,
neutropenia and thrombocytopenia was 17.1, 61.0 and 53.7% respectively. Only one patient had neutropenic sepsis and none of the
patients suffered from haemorrhage. Grade 3 or 4 nonhaematological toxicity was minimal and stem cell mobilisation was not
inhibited. GEM-P is an effective salvage regimen and its use prior to autologous stem cell transplant warrants further investigation.
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Several advances in the last decade in the treatment of Hodgkin’s
and non-Hodgkin’s lymphoma (NHL) have led to improved rates
of cure. The combination of chemotherapy with radiotherapy for
limited stage Hodgkin’s lymphoma (HL) and the introduction of
dose-intensified BEACOPP (bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine and prednisolone)
for poor prognosis advanced stage HL have improved relapse-free
survival in patients (Canellos et al, 1992; Noordijk et al, 1997;
Sieber et al, 2002). The adoption of ABVD (doxorubicin,
bleomycin, vinblastine and dacarbazine) as standard first-line
therapy for advanced HL has led to higher response rates (RRs)
with less treatment related toxicity (Canellos et al, 1992). The
addition of rituximab to conventional chemotherapy has improved
RRs and time to treatment failure in follicular lymphoma (Marcus
et al, 2003), while also improving overall survival in diffuse large
B-cell lymphoma (DLBCL) (Coiffier et al, 2002). Despite these
improvements in treatment, approximately 50% of patients with
advanced disease will relapse or fail treatment with first line
chemotherapy (Fisher et al, 1994; Canellos and Niedzwiecki, 2002;
Coiffier et al, 2002). However, salvage chemotherapy followed by
high-dose chemotherapy and autologous stem cell transplant
(ASCT) in patients with chemo-sensitive HL and aggressive NHL
can lead to long-term remission in 46–55% of patients (Linch et al,
1993; Philip et al, 1995; Schmitz et al, 2002).
At present, there is no accepted standard salvage chemotherapy.
Regimens that are commonly employed are usually cisplatin based
such as DHAP (dexamethasone, cytosine arabinoside and cispla-
tin) (Velasquez et al, 1988) and ESHAP (etoposide, methylpredni-
solone, cytosine arabinoside and cisplatin) (Velasquez et al, 1994)
or utilise an ifosfamide–etoposide backbone such as ICE
(ifosfamide, carboplatin and etoposide) (Moskowitz et al, 1999)
or MINE (mitoguanzone, ifosfamide, vinorelbine, etoposide)
(Ferme et al, 1995). Gemcitabine is a novel nucleoside analogue,
which is active in solid tumours such as pancreatic, ovarian and
non-small cell lung cancer (Burris et al, 1997; Manegold et al,
1997). In vitro studies of gemcitabine have demonstrated its ability
to circumvent multi-drug resistance (MDR) secondary to increased
P-glycoprotein and MDR protein 1 overexpression (Bergman et al,
2003). These MDR cells are associated with increased deoxycyti-
dine kinase activity and reduced deoxycytidine deaminase activity
leading to accumulation and increase sensitivity to gemcitabine
(Bergman et al, 2001). Preclinical studies of gemcitabine and
cisplatin have demonstrated synergy both in vitro and in vivo
(Peters et al, 1995). Phase I studies evaluating this combination in
relapsed and refractory HL and NHL have also reported higher
RRs (Aviles et al, 2004; Emmanouilides et al, 2004) compared to
either agent given as monotherapy (Fossa et al, 1999; Santoro et al,
2000; Savage et al, 2000; Zinzani et al, 2000). The mechanisms
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sunderlying this synergy may be due to increased incorporation of
gemcitabine into DNA and RNA, and increased cisplatin–DNA
adduct formation by inhibition of exonuclease and DNA repair
(van Moorsel et al, 1999). Given their synergism, absence of
significant overlapping toxicities and non-cross-resistance with
other regimens, gemcitabine in combination with cisplatin,
presents an attractive treatment option. Furthermore, treatment
with gemcitabine and cisplatin have been shown to induce
responses in patients with ovarian carcinoma previously resistant
to cisplatin or gemcitabine (Rose et al, 2003). We previously
reported a RR of 80% with GEM-P in 20 patients with relapsed and
refractory lymphoma, having met our target of excluding a lower
RR of 20% (Chau et al, 2003). Following our initial report, we
expanded our study to recruit a further 20 patients and now
present the results for all 42 patients, having established a more
precise estimate of the effectiveness of this regimen.
MATERIALS AND METHODS
The study was approved by the institution research and ethics
committees. Signed, written informed consent was obtained from
each patient.
Patients selection and evaluation
Patients aged over 18 years with histology-proven diagnosis of HD
and NHL were eligible (previous diagnoses were reformulated
according to the World Health Organization (WHO) classification
of lymphoid neoplasms) (Harris et al, 2000). They had to have
documented relapse or progressive disease following previous
chemotherapy; uni-dimensional measurable disease on computed
tomography (CT) scan; WHO performance status 0–2; no previous
therapy with either a platinum compound or gemcitabine.
Adequate bone marrow and hepatic function with a glomerular
filtration rate of 460mlmin
 1 was also required. Patients with
acquired immunodeficiency syndrome (AIDS)-related lymphoma,
positive human immunodeficiency virus serology and hearing
impairment were excluded. Pretreatment staging was by CT scans
of the chest, abdomen, pelvis (and neck if indicated); bone marrow
biopsy for all NHL patients and for HD patients with documented
bone marrow infiltration in the past or clinical suspicion of bone
marrow involvement with current relapse.
Chemotherapy regimen
Gemcitabine (1000mgm
 2) was delivered as an intravenous
infusion over 30min on days 1, 8 and 15. Cisplatin (100mgm
 2)
was given over 4h on day 15 only. Cisplatin was started 4h after
gemcitabine infusion. Pre- and post-chemotherapy hydration was
given on the day of cisplatin administration. Patients also received
methylprednisolone 1000mg either orally or intravenously on days
1–5. The cycle was repeated every 28 days.
Dose modifications
Toxicity was assessed according to WHO toxicity criteria. On the
day of treatment, if the neutrophil count was 0.5–0.9 10
9l
 1 and/
or the platelet count was 50–74 10
9l
 1, the gemcitabine dose was
reduced by 25%. If the neutrophil count was o0.5 10
9l
 1 and/or
the platelet count was o50 10
9l
 1, both gemcitabine and
cisplatin were withheld. Patients with febrile neutropenia were
given granulocyte-colony-stimulating factor (G-CSF) and both
gemcitabine and cisplatin were withheld until haematological
recovery, with subsequent dose reductions by 25%. In the event of
grade 3 or 4 nonhaematological toxicity, gemcitabine and cisplatin
doses were reduced by 25 and 50%, respectively. With the first
occurrence of transient tinnitus, cisplatin dose was reduced to
80mgm
 2 and with a second occurrence, the dose was further
reduced to 60mgm
 2. Cisplatin was discontinued in patients with
unresolved or recurrent tinnitus. Patients who developed renal
impairment had their cisplatin dose adjusted according to their
EDTA clearance.
Dose intensity
Owing to the heterogeneity of the study population, the planned
treatment duration was different between patients. Dose intensity
for each drug was calculated using the total administered dose
density for all patients divided by the total planned dose density
for all patients.
Autologous stem cell transplantation
Patients undergoing high-dose chemotherapy and ASCT following
GEM-P were required to have a stem cell harvest of 41.5 10
6
CD34þ cellskg
 1. The myeloablative regimens used were
melphalan and etoposide (ME) or melphalan, carmustine and
etoposide (MBE).
Evaluation of response
Tumour response was measured by CT scan after every two cycles
and at the end of treatment in accordance to the Response
Evaluation Criteria in Solid Tumours (RECIST) Guidelines
(Therasse et al, 2000). Bone marrow biopsy was repeated at the
end of treatment for patients with lymphomatous involvement
prior to treatment. Complete response (CR) was defined as the
disappearance of all target lesions, without the appearance of new
lesion(s) and absence of lymphomatous involvement on bone
marrow biopsy. Partial response (PR) was defined as at least a 30%
decrease in the sum of the longest diameter of target lesions, taking
as reference the baseline sum of the longest diameters. Progressive
disease (PD) was defined as at least a 20% increase in the sum of
the longest diameter of target lesions, taking as reference the
smallest sum of the longest diameters recorded since treatment
started or by the appearance of new lesions. Stable disease (SD)
was defined as neither sufficient shrinkage to qualify for PR nor
sufficient increase to qualify for PD, taking as reference the
smallest sum of the longest diameters since the treatment started.
The RECIST criteria were chosen because of the heterogeneity of
the patient population, which included both patients with HL and
NHL, as well as those with visceral disease. In these patients,
neither the Cotswold criteria (Lister et al, 1989) nor the
International Workshop NHL response criteria (Cheson et al,
1999) could be strictly applied.
Statistical analysis
The trial was initially performed using a Gehan’s two-stage design
for estimating the RR. However, after recruiting 21 patients, the
trial was stopped as the target of excluding a lower of 20% was
achieved. The trial was then expanded to recruit 42 patients in total
to obtain a point estimate of the RR with a confidence interval
of 715%.
Progression-free survival (PFS) and overall survival (OS) were
estimated using the Kaplan–Meier method. Progression-free
survival was calculated from the start of chemotherapy to the
date of relapse, progression or last follow-up. Overall survival was
estimated from the start of chemotherapy to the date of death from
any cause.
RESULTS
Between January 2001 and July 2003, 42 patients were recruited
from two centres into the study. One patient became ineligible
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sduring treatment, as the relapse was found to be from a new
colorectal cancer, and has been excluded from analysis. One
patient had a protocol violation as he received rituximab at cycle 4,
following an earlier partial response but has been included in the
analysis. The baseline characteristics of patients are shown in
(Table 1). The median age was 42 years, with the majority of
patients having nodular sclerosing HL (39%) or DLBCL (24%).
Nearly three-quarters of patients had advanced stage disease, while
26 patients (63%) had an elevated lactate dehydrogenase (LDH)
and 13 patients (32%) had B symptoms. Table 2 lists their disease
status and the previous treatments they received at study entry.
The median number of prior chemotherapy regimens was 2 with a
maximum of 5. Six patients had previously undergone ASCT,
seven patients had received rituximab while 18 (44%) had been
treated with radiotherapy. In all, 24 patients (59%) were in second
or subsequent relapse, 29 patients (71%) had primary progressive
disease or relapsed within a year and 19 patients (46%) had
chemo-resistant disease.
Response to treatment and survival
A total of 39 patients were evaluable for response, as two patients
did not have measurable disease. The best-achieved RR was 79%
(95% confidence interval (CI) 64–91) with eight patients (21%)
obtaining a CR and 23 patients (58%) obtaining a PR. GEM-P was
active across the spectrum of histological subtypes, and in chemo-
resistant disease the RR was 63% (Table 3). In first relapse and
primary progressive disease the RR was 78 and 50%, respectively.
After a median follow-up of 571 days, 26 patients are still alive. The
median PFS is 186 days (95% CI 117–255) and estimated overall
survival at 3 years is 54% (95% CI 33–71) (Figure 1).
Dose intensity and treatment toxicity
A total of 137 cycles were administered and the median number of
cycles per patient was 3 (range 1–6). The reasons for cessation of
treatment were a planned decision (n¼20), treatment failure
(n¼16), patient choice (n¼3) and toxicity (n¼2). The three
patients who chose to stop treatment were psychologically unable
to cope with further chemotherapy. Two other patients stopped
treatment because of lethargy and tinnitus. In all, 24 patients
(59%) experienced dose delays primarily due to myelosuppression,
while eight patients received G-CSF. The dose intensity for
gemcitabine and cisplatin was 81.2 and 72.3%. respectively. Eight
patients discontinued cisplatin, three from ototoxicity, two from
lethargy, two from dehydration with renal impairment and one for
an unspecified reason. Toxicity from treatment as assessed by
WHO criteria is listed in (Table 4). The incidence of grade 3 or 4
neutropenia and thrombocytopenia was 61.0% and 53.7%,
respectively; however, only one patient had neutropenic sepsis
and none suffered from haemorrhage. Grade 3 or 4 nonhaemato-
Table 1 Patient baseline characteristics
Characteristics Number of patients
Eligible patients 41
Age (years)
Median 42
Range 17–68
Sex
M:F 29:12
WHO performance status
01 3
12 3
25
B symptoms
Yes 13
No 28
Stage
1–2 11
3–4 30
LDH
pULN 15
4ULN 26
Extra-nodal sites
o23 5
X26
Histology
Hodgkin’s lymphoma
Nodular sclerosing 16
Lymphocyte predominant 1
B-cell type
Follicular Lymphoma Grade 1–3A 3
Diffuse large B-cell lymphoma 10
T-cell-rich B-cell lymphoma 2
Mantle cell lymphoma 1
T-cell type
T/NK cell 1
Angioimmunoblastic lymphoma 1
Anaplastic large cell lymphoma 3
Enteropathy associated lymphoma 1
Table 2 Disease status at trial entry and previous treatments
Previous treatment details
Prior lines of chemotherapy
Median (range) 2( 1 – 5 )
11 8
21 2
3X 11
Prior high-dose chemotherapy
Yes 6
No 35
Prior radiotherapy
Yes 18
No 23
Prior rituximab
Yes 7
No 34
Disease status
Primary progressive
a 8 patients
1st relapse 9 patients
2nd relapse 11 patients
3rd and subsequent relapse 13 patients
Remission duration
b
o 1 year 29 patients
4 1 year 12 patients
Chemosensitive
c 22
Chemoresistant
d 19
aDisease progression during or within 90 days of completion of induction treatment.
bDisease-free interval from end of last treatment till relapse.
cResponse to prior
chemotherapy lasting greater than 90 days from completion of treatment.
dDisease
progression during or within 90 days of completion of last chemotherapy.
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slogical toxicity was limited to nausea and vomiting, diarrhoea,
neuropathy and lethargy. Their incidence was 2.4%, 4.8%, 2.4%
and 2.5%, respectively. The patient with grade 3 neuropathy at the
start of treatment had cord compression, which improved
following a complete response to chemotherapy.
Treatment consolidation
Twenty-two patients were planned for high-dose consolidation
with ASCT following GEM-P. Of these patients, seven were in first
relapse, six had primary refractory disease, seven were in second
relapse and two were in third relapse. Eight patients underwent
ASCT , the remaining patients did not undergo ASCT due to
treatment failure (n¼10), patient choice (n¼2), cardiac insuffi-
ciency (n¼1) and subclavian vein thrombosis (n¼1). Stem cell
harvesting was performed in nine patients, the median CD 34þ
cell count was 2.25 10
6kg
 1 (range 1.65–3.21). The median time
to engraftment to achieve a neutrophil count 40.5 10
9l
 1 was 11
days (10–18) and to achieve a platelet count 420 10
9l
 1 was 10
days (8–12). There was no ASCT treatment-related mortality.
Following ASCT, five patients remain in remission while three
patients have relapsed of whom one has died. Autologous stem cell
transplant was not planned in the other 19 patients because of
previous ASCT (n¼6), indolent histology (n¼6), multiply
relapsed disease (n¼5), age (n¼1) and physician’s decision
(n¼1). Three of these patients received involved field radio-
therapy as consolidation following treatment with GEM-P, one of
whom has relapsed and all three are still surviving.
DISCUSSION
The RRs that we have observed with GEM-P is encouraging and
comparable to other salvage regimens (Velasquez et al, 1988, 1994;
Moskowitz et al, 1999). Of particular importance, these responses
are seen in a heavily pretreated population with several poor
prognostic features such as chemo-resistant disease (Josting et al,
2000), relapse within a year (Brice et al, 1997; Guglielmi et al,
1998), advanced disease stage (Blay et al, 1998) and previous
ASCT. Response to salvage chemotherapy is important prior to
ASCT, as it is correlated with survival post-transplant (Philip et al,
1987; Brice et al, 1997). Another significant finding was that
treatment with GEM-P did not appear to inhibit stem cell
harvesting, although this was not an end point of the study.
Myelosuppression was the main toxicity leading to treatment
delays; however, only one patient developed neutropenic sepsis
and eight patients received G-CSF. This may have been
accentuated by half of the patients having receiving two or more
lines of prior chemotherapy. From our ongoing experience with
GEM-P, by administering G-CSF on the 5th and 6th day after each
dose of gemcitabine, delays from neutropenia can be circum-
vented. Grade 3 or 4 nonhaematological toxicity was minimal and
we did not observe any cases of pulmonary toxicity. Several studies
have reported the development of severe pulmonary toxicity in
association with gemcitabine. The incidence of pulmonary toxicity
has been estimated to vary from 0 to 5% (Roychowdhury et al,
2002; Barlesi et al, 2003) and may be increased by administering
bleomycin (Friedberg et al, 2003; Bredenfeld et al, 2004) or
docetaxel (Dunsford et al, 1999; Kouroussis et al, 2004) in
combination with gemcitabine. In the above-mentioned study by
Bredenfeld et al, gemcitabine was given on days 1 and 4 of each
Table 3 Best-achieved response rates
No of patients CR PR SD PD RR % (95% CI)
Evaluable patients 39
a 8 23 4 4 79 (64–91)
Primary progressive 8 0 4 2 2 50 (16–84)
1st relapse 8 2 5 1 0 88 (47–100)
2nd and subsequent relapse 23 6 14 1 2 87 (66–97)
Chemosensitive 20 5 14 1 0 95 (75–100)
Chemoresistant 19 3 9 3 4 63 (38–84)
Hodgkin’s lymphoma 17 2 12 1 2 82 (57–96)
DLBCL 1 2 5 2 2 64 (31–89)
Follicular lymphoma 3 1 1 1 0 67 (9–99)
Mantle cell lymphoma 2 0 2 0 0 100 (16–100)
T-cell lymphoma 6 3 3 0 0 100 (29–100)
aTwo patients were not included in response evaluation due to absence of measurable disease.
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Figure 1 Overall survival and progression-free survival.
Table 4 Toxicity profile
Maximum WHO toxicity grade
which occurred (% of patients)
0 1 or 2 3 4
Anaemia 9.8 73.1 14.6 2.5
Leucopenia 4.9 36.6 31.7 26.8
Neutropenia 17 22 31.7 29.3
Thrombocytopenia 12.2 34.1 29.3 24.4
Infection 51.2 46.4 0 2.4
Haemorrhage 100 0 0 0
Nausea and vomiting 43.9 53.7 2.4 0
Stomatitis 70.7 29.3 0 0
Diarrhoea 63.4 31.8 2.4 2.4
Neuropathy 53.7 43.9 2.4 0
Ototoxicity 58.5 41.4 0 0
Renal impairment 56.1 43.9 0 0
Lethargy 32.5 65 2.5 0
Aloplecia 80.5 19.5 0 0
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s3 weekly cycle and the dose was increased from 800 to
1500mgm
 2. These differences may account for the absence of
pulmonary toxicity seen in our study. All of the patients who
developed renal impairment improved, with resolution in most.
Only two patients required discontinuation of treatment with
cisplatin, following which their renal impairment resolved to
Grade 0 and 1, respectively. The most common nonhaematological
toxicity was lethargy, which led to two patients stopping their
treatment. As a result, patients who were suitable for ASCT
received a median of 2 cycles of chemotherapy (range 2–4). In
addition, the GEM-P regimen does not contain alkylating agents or
etoposide, thereby reducing the risk of secondary haematological
malignancies in patients undergoing potentially curative treat-
ment.
Future directions with the GEM-P regimen would look to
increase its efficacy and reduce the toxicity of treatment.
Rituximab has been shown to enhance cytotoxicity with cisplatin
and overcome resistance to cisplatin and gemcitabine in-vitro
(Demidem et al, 1997; Emmanouilides et al, 2002). Combination of
rituximab with GEM-P may lead to improved CR rates similar to
that seen with rituximab and ICE (Kewalramani et al, 2004). This
may be important as some studies suggest that patients who
undergo ASCT in CR do better than those in PR (Moskowitz et al,
1999). Oxaliplatin, which is a diaminocyclohexane platinum, has
an RR of 40% in patients with relapsed and refractory NHL, and is
also active in patients resistant to cisplatin (Germann et al, 1999).
As oxaliplatin is not associated with nephrotoxicity and ototoxicity
(Chau et al, 2001), it may be an alternative for patients who are not
suitable or who discontinue treatment with cisplatin because of
nephrotoxicity and ototoxicity. Another way to enhance the
cytotoxicity of gemcitabine is to administer it as a fixed dose rate
infusion, this has been shown to improve drug delivery into
tumour cells (Grunewald et al, 1992). Phase I studies of fixed dose
rate gemcitabine infusion in combination with cisplatin and
dexamethasone have reported an RR of 45% in relapsed and
refractory lymphoma (Emmanouilides et al, 2004).
Gemcitabine in combination with cisplatin and methylpredni-
solone is an effective salvage regimen in patients with relapsed and
refractory lymphoma. As it is well tolerated, with minimal severe
nonhaematological toxicity and does not appear to inhibit stem
cell harvesting, it should be considered for use as reinduction
therapy prior to ASCT. Further studies to improve its efficacy and
to compare it with existing salvage regimens are warranted.
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